The growing field of immuno-oncology is centered on exploiting the immune system's own defenses against malignancies. Among these methods, inhibiting MAGEA3 with engineered antibodies holds great promise. MAGEA3, a part of the melanoma-associated antigen family, is often overexpressed in a selection of solid tumors, making it an suitable focus f… Read More